Journal Browser

► Journal Browser

Special Issue "New Therapies and Precision Medicine in Chronic Kidney Diseases"

Share This Special Issue

Special Issue Editors

E-Mail Website
Guest Editor

Keelung Chang Gung Memorial Hospital, Chang Gung University, Taipei, Taiwan
Interests: chronic kidney disease; gut microbiome; uremia

Dr. Chia-Te Liao
E-Mail Website
Guest Editor

Division of Nephrology, Department of Internal Medicine, Taipei Medical University - Shuang Ho Hospital, New Taipei City, Taiwan
Interests: nephrology and precision medicine

Special Issue Information

Dear Colleagues,

Chronic kidney disease is a major health and socioeconomic burden with heterogenous etiologies. High-throughput omics approaches have revolutionized biomarker research and have helped to advance our understanding of kidney diseases.

For this Special Issue, we welcome studies involving breakthroughs in omics and the application of systems biology to improve accurate functional and molecular disease classification during clinical practice. With the increase in knowledge and the development of computational models, precision medicine should improve diagnosis, prognosis and personalized treatment by targeting the right patient at the right time with the right intervention.

Dr. I-Wen Wu
Dr. Chia-Te Liao
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

chronic kidney disease
epigenomics
genomics
metabolomics
microbiome
proteomics
transcriptomics
precision medicine
personalized medicine

Published Papers (2 papers)

Download All Papers

Order results

Result details

Show export options Show export options

Select all

Export citation of selected articles as:

Research

Open AccessArticle

Potential Plasma Metabolite Biomarkers of Diabetic Nephropathy: Untargeted Metabolomics Study

and

J. Pers. Med. 2022, 12(11), 1889; https://doi.org/10.3390/jpm12111889 - 11 Nov 2022

Cited by 1 | Viewed by 944

Abstract

Diabetic nephropathy (DN) is one of the specific complications of diabetes mellitus and one of the leading kidney-related disorders, often requiring renal replacement therapy. Currently, the tests commonly used for the diagnosis of DN, albuminuria (AU) and glomerular filtration rate (GFR), have limited sensitivity and specificity and can usually be noted when typical morphological changes in the kidney have already been manifested. That is why the extreme urgency of the problem of early diagnosis of this disease exists. The untargeted metabolomics analysis of blood plasma samples from 80 patients with type 1 diabetes and early and late stages of DN according to GFR was performed using direct injection mass spectrometry and bioinformatics analysis for diagnosing signatures construction. Among the dysregulated metabolites, combinations of 15 compounds, including amino acids and derivatives, monosaccharides, organic acids, and uremic toxins were selected for signatures for DN diagnosis. The selected metabolite combinations have shown high performance for diagnosing of DN, especially for the late stage (up to 99%). Despite the metabolite signature determined for the early stage of DN being characterized by a diagnostic performance of 81%, these metabolites as potential biomarkers might be useful in the evaluation of treatment of the disease, especially at early stages that may reduce the risk of kidney failure development. Full article

(This article belongs to the Special Issue New Therapies and Precision Medicine in Chronic Kidney Diseases)

► Show Figures

Figure 1

Open AccessArticle

Effect of Dialysis Modalities on All-Cause Mortality and Cardiovascular Mortality in End-Stage Kidney Disease: A Taiwan Renal Registry Data System (TWRDS) 2005–2012 Study

and

J. Pers. Med. 2022, 12(10), 1715; https://doi.org/10.3390/jpm12101715 - 14 Oct 2022

Cited by 2 | Viewed by 953

Abstract

Introduction: End-stage kidney disease (ESKD) patients who need renal replacement therapy need to face a dialysis modality decision: the choice between hemodialysis (HD) and peritoneal dialysis (PD). Although the global differences in HD/PD penetration are affected by health-care policies, these two modalities may exert different effects on survival in patients with ESKD. Although Taiwan did not implicate PD as first policy, we still need to compare patients’ outcomes using two modalities in a nation-wise database to determine future patients’ care and health policies. Methods: We used the nationwide Taiwan Renal Registry Data System (TWRDS) database from 2005 to 2012 and included 52,900 patients (48,371 on HD and 4529 on PD) to determine all-cause and cardiovascular mortality among ESKD patients. Results: Age-matched survival probability from all-cause mortality was significantly lower in patients on PD than in those on HD (p < 0.05). The adjusted hazard ratios of 3-year and 5-year all-cause and cardiovascular mortality were significantly higher in PD compared with HD. The presence of comorbid conditions including myocardial infarction, coronary artery disease (CAD), diabetes mellitus (DM), hypoalbuminemia, hyperferritinemia and hypophosphatemia was related with significantly higher all-cause and CV mortality in PD patients. No significant difference was noted among younger patients <45 years of age regardless of DM and/or comorbid conditions. Conclusion: Although PD did not have the survival advantage compared to HD in all dialysis populations, PD was related with superior survival in younger non-DM patients, regardless of the presence of comorbidities. Similarly, for younger ESKD patients without the risk of CV disease, both PD and HD would be suitable dialysis modalities. Full article

(This article belongs to the Special Issue New Therapies and Precision Medicine in Chronic Kidney Diseases)

► Show Figures

Journal Menu

Journal Browser

Special Issue "New Therapies and Precision Medicine in Chronic Kidney Diseases"

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Published Papers (2 papers)

Research

Further Information

Guidelines

MDPI Initiatives

Follow MDPI